BCM
LYRA

Bridgeway Capital Management’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Bridgeway Capital Management’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,736
Closed -$540K – 1313
2024
Q1 		$540K Sell
1,736
-1,100
-39% -$293K 0.01% 905
2023
Q4 		$743K Hold
2,836
– – 0.02% 833
2023
Q3 		$554K Buy
2,836
+900
+46% +$161K 0.01% 850
2023
Q2 		$398K Sell
1,936
-1,000
-34% -$139K 0.01% 969
2023
Q1 		$304K Hold
2,936
– – 0.01% 1004
2022
Q4 		$461K Buy
2,936
+1,798
+158% +$356K 0.01% 899
2022
Q3 		$285K Hold
1,138
– – 0.01% 1058
2022
Q2 		$321K Sell
1,138
-200
-15% -$54.4K 0.01% 983
2022
Q1 		$269K Hold
1,338
– – 0.01% 1109
2021
Q4 		$292K Sell
1,338
-40
-3% -$12.8K 0.01% 1106
2021
Q3 		$630K Buy
1,378
+540
+64% +$204K 0.01% 967
2021
Q2 		$336K Sell
838
-142
-14% -$64.7K 0.01% 1185
2021
Q1 		$568K Hold
980
– – 0.01% 1056
2020
Q4 		$559K Buy
+980
New +$552K 0.01% 906

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's LYRA Position: Q2 2024 in Review

Bridgeway Capital Management sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2024, closing a stake of 1,736 shares — an estimated $540K sold.

Bridgeway Capital Management first reported a position in LYRA in Q4 2020 and held it in 14 quarters. The position peaked at $743K in Q4 2023. 51 funds tracked by Wall St. Rank hold LYRA as of Q2 2024.

  • Bridgeway Capital Management reported no remaining LYRA THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 1,736 LYRA THERAPEUTICS INC shares in Q2 2024, an estimated $540K.
  • Bridgeway Capital Management first reported a position in LYRA THERAPEUTICS INC in Q4 2020 and held it in 14 quarters.
  • Bridgeway Capital Management's LYRA THERAPEUTICS INC position peaked at $743K in Q4 2023.
  • 51 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2024.

Based on Bridgeway Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.